Gline Matthew bought ROIV
March 30, 2026 · Form 4 insider transaction
Gline Matthew bought 97,319 shares of Roivant Sciences Ltd., a transaction worth N/A. The trade was recorded as option exercise and disclosed on an SEC Form 4, filed 2 days after the transaction.
Footnotes
Reflects the conversion of capped value appreciation rights ("CVARs") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the applicable hurdle price reflected in column 8 of Table II above (such excess, the "CVAR Amount").; On March 30, 2026, the hurdle price applicable to 2,178,150 vested CVARs was satisfied and, accordingly, the CVARs were settled into 97,319 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on March 30, 2026.